• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Johnson & Johnson

    6/25/26 5:13:18 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JNJ alert in real time by email
    jnj-20260624
    FALSEFALSE00002004060000200406P1Y0.5iso4217:USDxbrli:purejnj:yearjnj:contract0000200406jnj:EBP100Member2025-01-012025-12-3100002004062025-01-012025-12-310000200406jnj:EBP100Member2025-12-310000200406jnj:EBP100Member2024-12-310000200406jnj:EBP100Member2024-01-012024-12-310000200406jnj:HiredBeforeMarch12017Memberjnj:EBP100Member2025-01-012025-12-310000200406jnj:HiredAfterMarch12017Memberjnj:EBP100Member2025-01-012025-12-310000200406jnj:EBP100Membersrt:MinimumMember2025-01-012025-12-310000200406jnj:EBP100Membersrt:MaximumMember2025-01-012025-12-310000200406us-gaap:ShortTermInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2025-12-310000200406us-gaap:ShortTermInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2024-12-310000200406us-gaap:ShortTermInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberjnj:EBP100Member2025-12-310000200406us-gaap:ShortTermInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberjnj:EBP100Member2024-12-310000200406us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2025-12-310000200406us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2024-12-310000200406us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberjnj:EBP100Member2025-12-310000200406us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberjnj:EBP100Member2024-12-310000200406us-gaap:DebtSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2025-12-310000200406us-gaap:DebtSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2024-12-310000200406us-gaap:DebtSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberjnj:EBP100Member2025-12-310000200406us-gaap:DebtSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberjnj:EBP100Member2024-12-310000200406us-gaap:EquitySecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2025-12-310000200406us-gaap:EquitySecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2024-12-310000200406us-gaap:EquitySecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberjnj:EBP100Member2025-12-310000200406us-gaap:EquitySecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberjnj:EBP100Member2024-12-310000200406us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2025-12-310000200406us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2024-12-310000200406us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberjnj:EBP100Member2025-12-310000200406us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberjnj:EBP100Member2024-12-310000200406jnj:LimitedPartnershipsAndCoInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2025-12-310000200406jnj:LimitedPartnershipsAndCoInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2024-12-310000200406jnj:LimitedPartnershipsAndCoInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberjnj:EBP100Member2025-12-310000200406jnj:LimitedPartnershipsAndCoInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberjnj:EBP100Member2024-12-310000200406jnj:OtherAssetsAndLiabilitiesNettingMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2025-12-310000200406jnj:OtherAssetsAndLiabilitiesNettingMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2024-12-310000200406jnj:OtherAssetsAndLiabilitiesNettingMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberjnj:EBP100Member2025-12-310000200406jnj:OtherAssetsAndLiabilitiesNettingMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMemberjnj:EBP100Member2024-12-310000200406jnj:EBP100Memberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMember2025-12-310000200406jnj:EBP100Memberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMember2024-12-310000200406jnj:EBP100Memberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMember2025-12-310000200406jnj:EBP100Memberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedPlanInterestInMasterTrustMember2024-12-310000200406jnj:EBP100Memberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMember2025-01-012025-12-310000200406jnj:EBP100Memberus-gaap:RepurchaseAgreementsMember2025-12-310000200406jnj:EBP100Memberus-gaap:RepurchaseAgreementsMember2024-12-310000200406us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberjnj:EBP100Memberjnj:PassiveMember2025-12-310000200406us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberjnj:EBP100Memberjnj:PassiveMember2024-12-310000200406us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberjnj:EBP100Memberjnj:ActiveMember2025-12-310000200406us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberjnj:EBP100Memberjnj:ActiveMember2024-12-310000200406jnj:EBP100Memberjnj:CommonCollectiveTrustU.S.EquitiesMember2025-12-310000200406jnj:EBP100Memberjnj:CommonCollectiveTrustU.S.EquitiesMember2024-12-310000200406jnj:EBP100Memberjnj:CommonCollectiveTrustGlobalEquitiesAndEmergingMarketsMember2025-12-310000200406jnj:EBP100Memberjnj:CommonCollectiveTrustGlobalEquitiesAndEmergingMarketsMember2024-12-310000200406jnj:EBP100Memberjnj:CommonCollectiveTrustFixedIncomeMember2025-12-310000200406jnj:EBP100Memberjnj:CommonCollectiveTrustFixedIncomeMember2024-12-310000200406jnj:EBP100Memberjnj:LimitedPartnershipsEmergingMarketLongOnlyEquityFundsMember2025-12-310000200406jnj:EBP100Memberjnj:LimitedPartnershipsEmergingMarketLongOnlyEquityFundsMember2024-12-310000200406jnj:EBP100Memberjnj:LimitedPartnershipsPrivateMarketFundsMember2025-12-310000200406jnj:EBP100Memberjnj:LimitedPartnershipsPrivateMarketFundsMember2024-12-310000200406jnj:EBP100Memberus-gaap:PrivateEquityFundsMember2025-12-310000200406jnj:EBP100Memberus-gaap:PrivateEquityFundsMember2024-12-310000200406us-gaap:PrivateEquityFundsMemberjnj:EBP100Memberjnj:CoInvestmentsMember2025-12-310000200406us-gaap:PrivateEquityFundsMemberjnj:EBP100Memberjnj:CoInvestmentsMember2024-12-310000200406jnj:EBP100Memberjnj:RealAssetsMember2025-12-310000200406jnj:EBP100Memberjnj:RealAssetsMember2024-12-310000200406jnj:EBP100Memberjnj:PrivateCreditMember2025-12-310000200406jnj:EBP100Memberjnj:PrivateCreditMember2024-12-310000200406jnj:EBP100Memberjnj:LimitedPartnershipsAndCoInvestmentsMember2025-01-012025-12-310000200406jnj:EBP100Memberjnj:LimitedPartnershipsAndCoInvestmentsMember2024-01-012024-12-310000200406us-gaap:ShortTermInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel1Member2025-12-310000200406us-gaap:ShortTermInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel2Member2025-12-310000200406us-gaap:ShortTermInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel3Member2025-12-310000200406us-gaap:ShortTermInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2025-12-310000200406us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel1Member2025-12-310000200406us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel2Member2025-12-310000200406us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel3Member2025-12-310000200406us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2025-12-310000200406us-gaap:DebtSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel1Member2025-12-310000200406us-gaap:DebtSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel2Member2025-12-310000200406us-gaap:DebtSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel3Member2025-12-310000200406us-gaap:DebtSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2025-12-310000200406us-gaap:EquitySecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel1Member2025-12-310000200406us-gaap:EquitySecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel2Member2025-12-310000200406us-gaap:EquitySecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel3Member2025-12-310000200406us-gaap:EquitySecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2025-12-310000200406us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel1Member2025-12-310000200406us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel2Member2025-12-310000200406us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel3Member2025-12-310000200406us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2025-12-310000200406jnj:LimitedPartnershipsAndCoInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel1Member2025-12-310000200406jnj:LimitedPartnershipsAndCoInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel2Member2025-12-310000200406jnj:LimitedPartnershipsAndCoInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel3Member2025-12-310000200406jnj:LimitedPartnershipsAndCoInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2025-12-310000200406jnj:OtherAssetsAndLiabilitiesNettingMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel1Member2025-12-310000200406jnj:OtherAssetsAndLiabilitiesNettingMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel2Member2025-12-310000200406jnj:OtherAssetsAndLiabilitiesNettingMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel3Member2025-12-310000200406jnj:OtherAssetsAndLiabilitiesNettingMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2025-12-310000200406us-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel1Member2025-12-310000200406us-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel2Member2025-12-310000200406us-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel3Member2025-12-310000200406us-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2025-12-310000200406us-gaap:ShortTermInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel1Member2024-12-310000200406us-gaap:ShortTermInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel2Member2024-12-310000200406us-gaap:ShortTermInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel3Member2024-12-310000200406us-gaap:ShortTermInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-12-310000200406us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel1Member2024-12-310000200406us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel2Member2024-12-310000200406us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel3Member2024-12-310000200406us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-12-310000200406us-gaap:DebtSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel1Member2024-12-310000200406us-gaap:DebtSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel2Member2024-12-310000200406us-gaap:DebtSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel3Member2024-12-310000200406us-gaap:DebtSecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-12-310000200406us-gaap:EquitySecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel1Member2024-12-310000200406us-gaap:EquitySecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel2Member2024-12-310000200406us-gaap:EquitySecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel3Member2024-12-310000200406us-gaap:EquitySecuritiesMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-12-310000200406us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel1Member2024-12-310000200406us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel2Member2024-12-310000200406us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel3Member2024-12-310000200406us-gaap:DefinedBenefitPlanCommonCollectiveTrustMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-12-310000200406jnj:LimitedPartnershipsAndCoInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel1Member2024-12-310000200406jnj:LimitedPartnershipsAndCoInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel2Member2024-12-310000200406jnj:LimitedPartnershipsAndCoInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel3Member2024-12-310000200406jnj:LimitedPartnershipsAndCoInvestmentsMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-12-310000200406jnj:OtherAssetsAndLiabilitiesNettingMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel1Member2024-12-310000200406jnj:OtherAssetsAndLiabilitiesNettingMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel2Member2024-12-310000200406jnj:OtherAssetsAndLiabilitiesNettingMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel3Member2024-12-310000200406jnj:OtherAssetsAndLiabilitiesNettingMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-12-310000200406us-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel1Member2024-12-310000200406us-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel2Member2024-12-310000200406us-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueInputsLevel3Member2024-12-310000200406us-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Memberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2024-12-310000200406jnj:EBP100Memberus-gaap-ebp:EmployeeBenefitPlanSyntheticInvestmentContractMember2025-12-310000200406jnj:EBP100Memberus-gaap-ebp:EmployeeBenefitPlanSyntheticInvestmentContractMember2024-12-310000200406us-gaap:ForeignExchangeForwardMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2025-12-310000200406us-gaap:ForeignExchangeForwardMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2024-12-310000200406us-gaap:ForeignExchangeFutureMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2025-12-310000200406us-gaap:ForeignExchangeFutureMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2024-12-310000200406us-gaap:InterestRateSwapMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2025-12-310000200406us-gaap:InterestRateSwapMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2024-12-310000200406us-gaap:CreditRiskContractMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2025-12-310000200406us-gaap:CreditRiskContractMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2024-12-310000200406us-gaap:SwaptionMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2025-12-310000200406us-gaap:SwaptionMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2024-12-310000200406us-gaap:TotalReturnSwapMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2025-12-310000200406us-gaap:TotalReturnSwapMemberus-gaap-ebp:EmployeeBenefitPlanNonconsolidatedMasterTrustMemberjnj:EBP100Member2024-12-310000200406jnj:EBP100Memberus-gaap:ForeignExchangeForwardMember2025-01-012025-12-310000200406jnj:EBP100Memberus-gaap:ForeignExchangeFutureMember2025-01-012025-12-310000200406jnj:EBP100Memberus-gaap:InterestRateSwapMember2025-01-012025-12-310000200406jnj:EBP100Memberus-gaap:CreditRiskContractMember2025-01-012025-12-310000200406jnj:EBP100Memberus-gaap:SwaptionMember2025-01-012025-12-310000200406jnj:EBP100Memberus-gaap:TotalReturnSwapMember2025-01-012025-12-310000200406jnj:EBP100Memberus-gaap:ForeignExchangeFutureMember2025-12-310000200406jnj:EBP100Memberus-gaap:ForeignExchangeFutureMember2024-12-310000200406jnj:EBP100Memberus-gaap:SwapMember2025-12-310000200406jnj:EBP100Memberus-gaap:SwapMember2024-12-310000200406us-gaap:ForeignExchangeContractMemberus-gaap:LongMemberjnj:EBP100Member2025-12-310000200406us-gaap:ForeignExchangeContractMemberus-gaap:LongMemberjnj:EBP100Member2024-12-310000200406us-gaap:ForeignExchangeContractMemberus-gaap:ShortMemberjnj:EBP100Member2025-12-310000200406us-gaap:ForeignExchangeContractMemberus-gaap:ShortMemberjnj:EBP100Member2024-12-310000200406us-gaap:FutureMemberus-gaap:LongMemberjnj:EBP100Member2025-12-310000200406us-gaap:FutureMemberus-gaap:LongMemberjnj:EBP100Member2024-12-310000200406us-gaap:FutureMemberus-gaap:ShortMemberjnj:EBP100Member2025-12-310000200406us-gaap:FutureMemberus-gaap:ShortMemberjnj:EBP100Member2024-12-310000200406us-gaap:SwaptionMemberus-gaap:LongMemberjnj:EBP100Member2025-12-310000200406us-gaap:SwaptionMemberus-gaap:LongMemberjnj:EBP100Member2024-12-310000200406us-gaap:SwaptionMemberus-gaap:ShortMemberjnj:EBP100Member2025-12-310000200406us-gaap:SwaptionMemberus-gaap:ShortMemberjnj:EBP100Member2024-12-310000200406jnj:EBP100Memberus-gaap:InterestRateSwapMember2025-12-310000200406jnj:EBP100Memberus-gaap:InterestRateSwapMember2024-12-310000200406jnj:EBP100Memberus-gaap:CreditDefaultSwapMember2025-12-310000200406jnj:EBP100Memberus-gaap:CreditDefaultSwapMember2024-12-310000200406jnj:EBP100Memberus-gaap:TotalReturnSwapMember2025-12-310000200406jnj:EBP100Memberus-gaap:TotalReturnSwapMember2024-12-310000200406jnj:MaturityOfOneYearMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-01-012025-12-310000200406jnj:MaturityOfOneYearMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-12-310000200406jnj:MaturityOfTwoYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-01-012025-12-310000200406jnj:MaturityOfTwoYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-12-310000200406jnj:MaturityOfThreeYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-01-012025-12-310000200406jnj:MaturityOfThreeYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-12-310000200406jnj:MaturityOfFourYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-01-012025-12-310000200406jnj:MaturityOfFourYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-12-310000200406jnj:MaturityOfFiveYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-01-012025-12-310000200406jnj:MaturityOfFiveYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-12-310000200406jnj:MaturityOfSixYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-01-012025-12-310000200406jnj:MaturityOfSixYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-12-310000200406jnj:MaturityOfSevenYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-01-012025-12-310000200406jnj:MaturityOfSevenYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-12-310000200406jnj:MaturityOfEightYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-01-012025-12-310000200406jnj:MaturityOfEightYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-12-310000200406jnj:MaturityOfNineYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-01-012025-12-310000200406jnj:MaturityOfNineYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-12-310000200406jnj:MaturityOfTenYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-01-012025-12-310000200406jnj:MaturityOfTenYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2025-12-310000200406jnj:MaturityOfOneYearMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2024-01-012024-12-310000200406jnj:MaturityOfOneYearMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2024-12-310000200406jnj:MaturityOfTwoYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2024-01-012024-12-310000200406jnj:MaturityOfTwoYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2024-12-310000200406jnj:MaturityOfThreeYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2024-01-012024-12-310000200406jnj:MaturityOfThreeYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2024-12-310000200406jnj:MaturityOfFourYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2024-01-012024-12-310000200406jnj:MaturityOfFourYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2024-12-310000200406jnj:MaturityOfFiveYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2024-01-012024-12-310000200406jnj:MaturityOfFiveYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2024-12-310000200406jnj:MaturityOfSevenYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2024-01-012024-12-310000200406jnj:MaturityOfSevenYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2024-12-310000200406jnj:MaturityOfEightYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2024-01-012024-12-310000200406jnj:MaturityOfEightYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2024-12-310000200406jnj:MaturityOfNineYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2024-01-012024-12-310000200406jnj:MaturityOfNineYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2024-12-310000200406jnj:MaturityOfTenYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2024-01-012024-12-310000200406jnj:MaturityOfTenYearsMemberus-gaap:CreditDefaultSwapMemberjnj:EBP100Member2024-12-310000200406jnj:EBP100Memberus-gaap-ebp:EmployeeBenefitPlanOtherRelatedPartyAndPartyInInterestMember2025-12-310000200406jnj:EBP100Memberus-gaap-ebp:EmployeeBenefitPlanOtherRelatedPartyAndPartyInInterestMember2024-12-310000200406us-gaap-ebp:EmployeeBenefitPlanAllocatedMemberjnj:EBP100Memberus-gaap-ebp:EmployeeBenefitPlanTrusteeMember2025-12-310000200406jnj:EBP100Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2025-12-310000200406jnj:EBP100Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2024-12-310000200406jnj:EBP100Memberus-gaap-ebp:EmployeeBenefitPlanEmployerCommonStockMember2025-01-012025-12-310000200406jnj:Serotiny401kPlanMemberjnj:EBP100Member2025-01-012025-12-310000200406jnj:ShockwaveMedical401kPlanMemberjnj:EBP100Member2025-01-012025-12-310000200406jnj:AmbryxInc.401kPlanMemberjnj:EBP100Member2025-01-012025-12-310000200406jnj:PatientServiceCenterLLCSavingsPlanMemberjnj:EBP100Member2025-01-012025-12-310000200406jnj:VWave401kPlanMemberjnj:EBP100Member2025-01-012025-12-310000200406jnj:EBP100Membersrt:MinimumMember2025-10-012025-10-310000200406jnj:EBP100Membersrt:MaximumMember2025-10-012025-10-31

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549
    FORM 11-K

    FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS
    AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934
    ------------------------------
    [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the Fiscal Year Ended December 31, 2025
    OR
    [ ] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    Commission File Number  1-3215

    ------------------------------
    JOHNSON & JOHNSON
    SAVINGS PLAN

    (Full title of the Plan)

    JOHNSON & JOHNSON
    ONE JOHNSON & JOHNSON PLAZA
    NEW BRUNSWICK, NEW JERSEY 08933

    (Name of issuer of the securities held pursuant to the Plan
    and the address of its principal executive office)



    REQUIRED INFORMATION

    Item 4.    Financial Statements and Supplemental Schedules

    Financial statements prepared in accordance with the financial reporting requirements of ERISA filed herewith are listed below in lieu of the requirements of Items 1 to 3.

    Report of Independent Registered Public Accounting Firm

    Financial Statements:

    Statements of Net Assets Available for Benefits

    Statement of Changes in Net Assets Available for Benefits

    Notes to Financial Statements

    Supplemental Schedules*:

    Schedule H, line 4i - Schedule of Assets (Held at End of Year)
    Schedule H, line 4a- Schedule of Delinquent Participant Contributions

    Signatures

    *Other supplemental schedules required by Section 2520.103-10 of the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974 (“ERISA”), as amended, have been omitted because they are not required or are not applicable.

    Exhibits:

    23.  Consent of PricewaterhouseCoopers LLP, dated June 25, 2026



    SIGNATURES


    The Plan.   Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.



    JOHNSON & JOHNSON SAVINGS PLAN
    Date: June 25, 2026
    By:
    /s/ Kristen Mulholland
    Kristen Mulholland
    Chairman, Pension and Benefits Committee







    JOHNSON & JOHNSON SAVINGS PLAN
    __________________


    FINANCIAL STATEMENTS AND
    SUPPLEMENTAL SCHEDULES


    DECEMBER 31, 2025 AND 2024


    Johnson & Johnson Savings Plan
    Index to Financial Statements and Supplemental Schedules







    Page(s)
    Report of Independent Registered Public Accounting Firm
    1
    Financial Statements:
    Statements of Net Assets Available for Benefits
    2
    Statement of Changes in Net Assets Available for Benefits
    3
    Notes to Financial Statements
    4 - 16
    Supplemental Schedules*:
    Schedule H, line 4i - Schedule of Assets (Held at End of Year)
    17
    Schedule H, line 4a - Schedule of Delinquent Participant Contributions18
    * Other supplemental schedules required by Section 2520.103-10 of the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974  (“ERISA”), as amended, have been omitted because they are not required or are not applicable.




    Report of Independent Registered Public Accounting Firm

    To the Administrator and Plan Participants of Johnson & Johnson Savings Plan

    Opinion on the Financial Statements

    We have audited the accompanying statements of net assets available for benefits of Johnson & Johnson Savings Plan (the “Plan”) as of December 31, 2025 and 2024 and the related statement of changes in net assets available for benefits for the year ended December 31, 2025, including the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2025 and 2024, and the changes in net assets available for benefits for the year ended December 31, 2025 in conformity with accounting principles generally accepted in the United States of America.

    Basis for Opinion

    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audits of these financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

    Supplemental Information

    The supplemental Schedule H, line 4a - Schedule of Delinquent Participant Contributions as of December 31, 2025 and for the year then ended and Schedule H, line 4i - Schedule of Assets (Held at End of Year) as of December 31, 2025 ("supplemental schedules") have been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental schedules are the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental schedules reconcile to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental schedule. In forming our opinion on the supplemental schedules, we evaluated whether the supplemental schedules, including their form and content, are presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental schedules are fairly stated, in all material respects, in relation to the financial statements as a whole.

    /s/ PricewaterhouseCoopers LLP
    New York, New York
    June 25, 2026


    We have served as the Plan’s auditor since at least 1987. We have not been able to determine the specific year we began serving as auditor of the Plan.

    1

    Johnson & Johnson Savings Plan
    Statements of Net Assets Available for Benefits




    December 31,
    20252024
    Assets
    Interest in Johnson & Johnson Pension and Savings Plans Master Trust, at fair value
    $26,758,159,368 $23,472,930,960 
    Total investments26,758,159,368 23,472,930,960 
    Receivables
    Employee contributions— 51,400 
    Employer contributions
    22,346,369 — 
                                      Notes receivable from participants96,395,432 93,770,955 
    Total receivables
    118,741,801 93,822,355 
                     Other assets16,998,655 18,799,879 
    Total assets
    26,893,899,824 23,585,553,194 
    Net assets available for benefits
    $26,893,899,824 $23,585,553,194 

    The accompanying notes are an integral part of these financial statements.
    2

    Johnson & Johnson Savings Plan
    Statement of Changes in Net Assets Available for Benefits




    Year Ended
    December 31,
    Additions to net assets attributed to2025
    Investment Income/Loss
    Plan's interest in the Johnson & Johnson Pension and Savings Plans Master Trust net
    investment income/loss
    $4,507,325,830 
    Contributions
    Employee contributions
    777,084,109 
    Employer contributions291,497,088 
    Total additions
    5,575,907,027 
    Deductions from net assets attributed to
    Benefits paid to participants
    2,335,557,439 
    Administrative expenses49,388,408 
    Total deductions
    2,384,945,847 
    Net increase/(decrease)3,190,961,180 
    Asset transfers due to plan mergers117,385,450 
    Net assets available for benefits
            Beginning of year 23,585,553,194 
           End of year
    $26,893,899,824 
    The accompanying notes are an integral part of these financial statements.
    3

    Johnson & Johnson Savings Plan
    Notes to Financial Statements

    1.    Description of the Plan
    General
    The Johnson & Johnson Savings Plan (the “Plan”) is a participant directed defined contribution plan which was established on June 1, 1982 for eligible salaried and certain hourly employees of Johnson & Johnson ("Johnson & Johnson” or the “Company”) and certain domestic subsidiaries.  The Plan was designed to enhance the existing retirement program of eligible employees.  The Plan is administered by the Pension & Benefits Committee (the "Plan Administrator") of Johnson & Johnson. The funding of the Plan is made through employee and Company contributions.  The net assets of the Plan are held in the Johnson & Johnson Pension and Savings Plans Master Trust (the “Trust” or "the Master Trust").  Transactions in the Trust are executed by the Trustee. Prior to October 1, 2025 the Trustee was State Street Bank and Trust Company (“State Street” or “Trustee”). Effective October 1, 2025, the Trustee is The Northern Trust Company ("Northern Trust" or "Trustee"). Recordkeeping services are provided by Alight Solutions. The Plan’s interest in the Trust is allocated to the Plan based upon the total of each participant’s share of the Trust.
    This brief description of the Plan is provided for general information purposes only.  Participants should refer to the Plan document for complete information.

    Contributions
    In general, full-time salaried employees and certain hourly, part-time and temporary employees can contribute to the Plan. There is no service requirement for employee contributions. If a participant does not take action to enroll or declines enrollment in the Plan within their first 30 days of employment, they will be automatically enrolled for pre-tax employee contributions equal to 6% of their eligible pay and these contributions will be invested in the Plan's default investment option. The Plan's default investment option is the Target Retirement Fund that aligns with, or is closest to, the year in which the participant will turn age 62.
    Contributions are made to the Plan by participants through payroll deductions and by the Company on behalf of the participants.  Participating employees may contribute a minimum of 3% up to a maximum of 50% of eligible pay, as defined by the Plan.  Contributions can be pre-tax, Roth, after-tax or a combination of all three.  Pre-tax and Roth contributions may not exceed the smaller of (i) 50% of a participant’s base salary (and 1/2 paid commissions, if applicable) or (ii) $23,500 for 2025.  The maximum contributions to a participant’s account including participant pre-tax, Roth and after-tax contributions and the Company match is $70,000 for 2025.
    Participants age 50 and over are eligible to contribute extra pre-tax and/or Roth contributions (“catch-up contributions”) above the annual Internal Revenue Service ("IRS") limitation up to $7,500 in 2025. Participants who will be age 60-63 by the end of 2025 can make catch-up contributions up to the limit of $11,250. Participants can elect an amount to be contributed from each paycheck as their catch-up contribution. This amount will be in addition to the pre-tax, Roth and after-tax contribution percentages that participants have elected. The catch-up contribution is not eligible for the Company matching contribution.
    Prior to January 1, 2025, participants received a Company matching contribution equal to 75% of the first 6% of a participant’s contributions. Effective January 1, 2025, participants receive a Company matching contribution equal to 75% of the first 6% pre-tax and Roth contributions. The Company matching contributions are made every payroll period. Effective January 1, 2025, following each Plan year, the Company will make a “true-up” matching contribution calculated under the same formula as the payroll period match but determined on an annual basis and reduced by the payroll period matching contributions received by the participant during the year. The Company matching contribution is comprised of cash and invested in the current investment fund mix chosen by the participant.
    Investments
    Participants may invest in one or more of the various investment funds offered by the Plan.  On January 1, 2025, the Plan introduced the Target Retirement 2065 Fund. Each of the Plan's funds represents a mix of various investments. The investment mix chosen by the participant will apply to employee and Company matching contributions.  Rollover contributions are invested at the election of the participant.

    Participants receive dividends on Johnson & Johnson common stock shares held in the Johnson & Johnson Common Stock Fund and Johnson & Johnson Stock Contributions Fund.  The dividends are automatically reinvested in the Johnson & Johnson Common Stock Fund unless specific elections are made to receive a cash payment.  The 2025 dividend pass-through amount paid to participants of $5,573,830 is reflected in benefits paid to participants in the
    4

    Johnson & Johnson Savings Plan
    Notes to Financial Statements

    Statement of Changes in Net Assets Available for Benefits.  For all other funds, the Trustee reinvests all dividend and interest income.

    Effective September 1, 2020, participants are not permitted to (1) direct more than 20% of any contribution made to the Plan to the Johnson & Johnson Common Stock Fund or (2) transfer or reallocate amounts into the Johnson & Johnson Common Stock Fund if, immediately after such transfer or reallocation, the aggregate value of their investments in the Johnson & Johnson Common Stock Fund and the Johnson & Johnson Stock Contributions Fund would exceed 20% of their aggregate Plan Balance. This limitation does not (a) affect investments resulting from transfers before September 1, 2020 or (b) restrict percentages in excess of 20% that result from investment performance or reinvestment of dividends.

    Vesting
    A participant's contributions (pre-tax, after-tax, Roth and rollover) and the earnings on them are always fully vested.

    For the Company matching contributions, if a participant was hired before March 1, 2017, the Company matching contributions were made to the participant's account after a one-year eligibility period was satisfied. These contributions and the associated earnings are fully vested. If a participant was hired on or after March 1, 2017, the Company matching contributions made to the participant's account, and the earnings on these contributions, become vested after the participant has completed a three-year period of service. These contributions become vested if, while employed by the Company, the participant should die, become disabled, or reach age 55. If the Company matching contributions and associated earnings are not vested when the participant employment ends, they will be forfeited unless the participant returns to employment with the Company before (1) taking a total distribution of their vested account balance and (2) incurs a break in service (a period of at least five consecutive years in which the participant is not employed by the Company).

    Forfeitures
    Forfeitures of non-vested Company contributions are used to reduce future Company contributions. During 2025 and 2024, $9,264,042 and $8,134,908, respectively, of forfeited participant accounts were used to reduce the Company's contributions. At December 31, 2025, there were $600,827 of forfeitures that have not yet been applied to reduce the Company's contributions.

    Payment of Benefits
    Participants who have not reached age 59 1/2 are allowed to withdraw an amount equal to their pre-August 1, 2003 after-tax contributions and earnings thereon, unmatched after-tax contributions made after August 1, 2003 by the employee and earnings thereon, rollover contributions and earnings thereon, and pre-2003 Company match and earnings thereon, at any time. Effective December 13, 2019, participants are able to withdraw from all vested contribution types upon meeting certain hardship conditions. Effective December 10, 2021, participants who have reached age 59 1/2 are allowed to withdraw all or any portion of their Plan account except Roth Contribution Accounts. Effective January 28, 2022, participants who have reached age 59 1/2 are allowed to withdraw all or any portion of their Plan account including Roth Contribution Accounts. The benefits to which participants are entitled are the amounts provided by contributions (Company and participant) and investment earnings thereon, including net realized and unrealized gains and losses which have been allocated to the participant’s account balance. Participants have the option of receiving all or part of their vested balance in the Johnson & Johnson Common Stock Fund and/or the Johnson & Johnson Stock Contributions Fund as either cash or in shares of Johnson & Johnson common stock (plus cash for fractional shares) for lump sum distributions other than a hardship.
    Benefits are also paid to participants upon termination of employment, long-term disability or retirement. Effective January 1, 2025, participants can elect to defer payment until (A) age 75 for members who attain age 73 after December 31, 2032 and, (B) age 73 for members who attain age 73 before January 1, 2033 and age 72 after December 31 2022, (C) age 72 for members who attain age 72 before January 1, 2023 and age 70 1/2 after December 31, 2019, or (D) age 70 1/2 for members who attain age 70 1/2 before January 1, 2020. Distributions are paid either in a lump sum payment, partial payments or installment payments made on a monthly, quarterly, or annual basis over a period of years selected by the participant.
    A participant’s vested account may be distributed to his/her beneficiaries in lump sum, partials, installments or maintained in the Trust upon the participant’s death only if the beneficiary is a spouse.  Otherwise, it is paid to the beneficiary in a lump sum, either directly or rolled over to an Individual Retirement Account ("IRA").
    5

    Johnson & Johnson Savings Plan
    Notes to Financial Statements

    Administrative Expenses
    To cover recordkeeping expenses for the Plan, each participant is charged an annual administration fee of $36, which is assessed on a monthly basis. Additionally, participants are subject to fees for transactions such as loan requests, domestic relations orders and legal documentation review. All other third-party administrative expenses are paid by the Plan, unless otherwise provided for by the Company.

    Notes Receivable from Participants
    Participants may borrow up to a maximum of 50% of their vested account balance.  The minimum loan amount is $1,000 and the maximum amount of all outstanding loans cannot exceed $50,000.  Loans bear an interest rate of prime plus 1% and the term of the loan is one to five years. Prior to September 3, 2025, the loan had to be outstanding for at least 12 months before a full repayment can be made. Effective September 3, 2025, loans can be repaid in full or in part at any time. Due to acquisitions, there are some existing loans extending beyond five years, which must be allowed to continue once transferred into the Johnson & Johnson Savings Plan. The collateralized balances in the participant’s accounts have interest rates that range from 3.25% to 11.33%.  Principal and interest is paid ratably through payroll deductions for active employees or by direct payment for inactive participants. 

    Prior to September 3, 2025,  loans were required to be repaid within two months following retirement or termination of employment with the Company. Effective September 3, 2025, participants who terminate employment may make arrangements to continue loan repayments in accordance with the loan's amortization schedule. If the loan is not repaid by the applicable deadline the unpaid balance, plus accrued interest, will be deducted from the participant’s account balance and reported to the IRS as a distribution.

        Termination
    Although it has not expressed an intent to do so, the Company has the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject to the provisions of ERISA.  In the event of a partial or full Plan termination, all Plan funds must be used exclusively for the benefit of the Plan participants, in that each participant would receive the respective value in their account.
    2. Summary of Significant Accounting Policies
    Basis of Accounting
    The financial statements of the Plan are prepared under the accrual method of accounting in accordance with accounting principles generally accepted in the United States of America.
    Investment Valuation and Income Recognition of the Trust
    The Plan’s interest in the Trust is stated at fair value, except for the fully benefit-responsive investment contracts which are stated at contract value. The investment in the Trust represents the Plan's interest in the net assets of the Trust.
    As the investment funds contain various underlying assets such as stocks and short-term investments, the participant’s account balance is reported in units of participation, which allows for immediate transfers in and out of the funds.  The purchase or redemption price of the units is determined by the Trustee, based on the current market value of the underlying assets of the funds.  Each fund’s net asset value for a single unit is computed by adding the value of the fund’s investments, cash and other assets, and subtracting liabilities, then dividing the result by the number of units outstanding.
    Purchases and sales of securities are recorded on a trade-date basis.  Gains and losses on the sale of investments are determined on the average cost method.  Dividend income is recorded on the ex-dividend date. Interest income and administrative expenses are recorded on an accrual basis.
    The Plan presents, in the Statement of Changes in Net Assets Available for Benefits, the net investment income/loss for the Plan's interest in the Trust which consists of the Plan’s allocated change in unrealized appreciation and depreciation of the underlying investments, realized gains and losses on sales of investments and investment income/loss based upon the total of each participant's share of the Trust.

    6

    Johnson & Johnson Savings Plan
    Notes to Financial Statements

    Payment of Benefits
    Benefit payments to participants are recorded upon distribution.
    Derivatives
    The Trust mitigates risk through structured trading with reputable parties and continual monitoring procedures. The Trust enters into forward foreign exchange contracts to hedge against adverse changes in foreign exchange rates related to non-U.S. dollar denominated investments. The Trust is exposed to credit risk for non-performance by the counterparty and to market risk for changes in interest and currency rates. The Trust accounts for forward foreign exchange contracts at fair value.

    The fair value of a forward foreign exchange contract is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate.

    The Trust actively manages risk by periodically investing in interest rate swaps, credit default swaps and fixed income options. Interest rate swaps are used to manage interest rate risk and provide an effective means to adjust portfolio duration, maturity mix and term-structure. Credit default swaps are used to either synthetically add or reduce credit risk to an individual issuer or a basket of issuers. Depending on the type of contract, the counterparty risk exposure can be either with the exchange or another counterparty. Fixed income options are used in various ways including: to pursue upside exposure to a portion of the yield curve, to capitalize on anticipated changes in market volatility, to focus on generating income, and to serve as a hedge. The Trust records interest rate swaps, credit default swaps and options at fair value. Interest rate swaps are valued daily using underlying yield curves based upon broker/dealer sources, the present value of expected cash flows, and frequency of which they compound and pay. Credit default swaps are valued using daily underlying yield curves and/or credit curves and spreads based upon broker/dealer/index sources, the present value of expected cash flows, and the frequency of which they compound and pay including a weighted default calculation. Options are fair valued using market-based inputs to models, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency, where such inputs and models are available. Alternatively, the values may be obtained through unobservable management determined inputs and/or management’s proprietary models. Where models are used, the selection of a particular model to value an option depends upon the contractual terms of, and specific risks inherent in, the option as well as the availability of pricing information in the market. Valuation models require a variety of inputs, including contractual terms, market prices, measures of volatility and correlations of such inputs.

    The Trust may also enter into total return swap contracts, which are contracts in which one party agrees to make periodic payments based on the change in market value of the underlying assets, which may include a specified security, basket of securities or security indexes during the specified period, in return for periodic payments based on a fixed or variable interest rate of the total return from other underlying assets. Total return swap agreements may be used to obtain exposure to a security or market without owning or taking physical custody of such security or market. Total return swaps involve not only the risk associated with the investment in the underlying securities, but also the risk of the counterparty not fulfilling its obligations under the agreement. Total return swaps are valued daily using underlying index levels for fixed and financing legs. The Trust determines the fair value of total return swaps based on published index prices. The total market value is the sum of the market value of both the fixed and the float legs. The market value of the fixed leg is determined by the change in price of the asset times the units. The market value of the float leg is determined by the accrued financing given the reset frequency and financing index. The Mark-to-Market (MTM) / swap value is collateralized daily.

    A futures contract is an agreement to buy or sell a security or other asset for a set price on a future date. These contracts are traded on major exchanges and are marked to market daily, thus minimizing counterparty risk. The Trust enters into futures contracts mainly to manage the duration and refine the curve positioning of the fixed income portfolios, thus, allowing the investment managers to achieve the overall investment portfolios' objectives. These contracts are traded on the exchange and the fair value is the daily mark to market, which is a function of price movements for the contract relative to the level it was originally entered into.
    There have been no changes in the methodologies used at December 31, 2025 and 2024.

    7

    Johnson & Johnson Savings Plan
    Notes to Financial Statements

    Use of Estimates
    The preparation of the Plan’s financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts in the Statements of Net Assets Available for Benefits at the date of the financial statements and the Statement of Changes in Net Assets Available for Benefits during the reporting period and the applicable disclosures of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates.
    Risks and Uncertainties
    The Plan provides for various investment options in funds which can invest in a combination of equity, fixed income securities and other investments. Investments are exposed to various risks, such as interest rate, market and credit.  Due to the level of risk associated with certain investments, it is at least reasonably possible that changes in risks in the near term could materially affect participants’ account balances and the amounts reported in the Statements of Net Assets Available for Benefits and the Statement of Changes in Net Assets Available for Benefits.
    Reporting of Fully Benefit-Responsive Investment Contracts
    Fully benefit-responsive investment contracts are reported at contract value. Contract value is the relevant measurement criteria for that portion of the net assets available for benefits of a defined contribution plan attributable to fully benefit-responsive investment contracts because contract value is the amount participants would receive if they were to initiate permitted transactions under the terms of the Plan.
    3.    Johnson & Johnson Pension and Savings Plans Master Trust
    The assets of the Johnson & Johnson Savings Plan, the Johnson & Johnson Retirement Savings Plan, the Retirement Plan of Johnson & Johnson and Affiliated Companies, the Johnson & Johnson Retirement Plan for Union Represented Employees, and the Johnson & Johnson Retirement Plan for Puerto Rico Employees comprise the total of the Trust which is held by the Trustee.
    8

    Johnson & Johnson Savings Plan
    Notes to Financial Statements

    The following table presents the net assets of the Master Trust and the Plan's interest in the net assets of the Master Trust as of December 31, 2025 and 2024.
     Savings Plan's
    Master Trust Interest in Master Trust
    2025202420252024
    ASSETS
    Investments, at fair value
    Short-term investment funds$837,401,795 $1,250,144,436 $206,318,324 $692,656,295 
    Government and agency securities7,909,637,860 6,702,640,214 800,180,333 495,174,353 
    Debt Instruments2,715,291,495 2,655,972,031 473,757,951 387,677,429 
    Equity Securities15,823,220,308 15,780,859,727 10,337,584,046 9,752,368,091 
    Common collective trusts18,002,382,609 14,649,283,090 13,445,991,078 10,394,318,582 
    Limited Partnerships/Co-Investments4,067,712,231 3,623,532,368 — 73,382,479 
    Other assets and liabilities, net(11,570,781)(101,772,978)5,041,861 4,507,805 
    Total Investments at Fair Value$49,344,075,517 $44,560,658,888 $25,268,873,593 $21,800,085,034 
    Other assets
    Guaranteed and synthetic investment
       contracts at contract value$1,635,918,229 $1,768,181,421 $1,576,802,634 $1,708,110,513 
    Receivable for investments sold1,178,126,254 409,180,700 12,559,513 38,447,263 
    Interest receivables68,163,126 76,491,082 11,723,419 10,260,403 
    Dividend receivables6,667,833 8,237,777 3,733,376 4,196,473 
    Other receivables11,476,531 9,170,067 5,573,931 5,918,884 
    Total Other Assets$2,900,351,973 $2,271,261,047 $1,610,392,873 $1,766,933,536 
    Total Master Trust assets$52,244,427,490 $46,831,919,935 $26,879,266,466 $23,567,018,570 
    LIABILITIES
    Payables for investments purchased$(771,321,464)$(578,825,229)$(106,998,760)$(82,707,185)
    All other payables(17,418,452)(62,778,061)(14,108,338)(11,380,425)
    Total Liabilities$(788,739,916)$(641,603,290)$(121,107,098)$(94,087,610)
    Net Master Trust assets$51,455,687,574 $46,190,316,645 $26,758,159,368 $23,472,930,960 

         The following table presents the changes in net assets for the Master Trust for the year ended December 31, 2025:
    2025
    Changes in Net Assets:
      Net appreciation (depreciation) in fair value of investments $6,680,997,213 
       Interest515,823,901 
       Dividends247,389,143 
            Total net investment income (loss)7,444,210,257 

    a.     Fair Value Measurements
    The Plan’s valuation methodologies were applied to all of the Trust's investments carried at fair value. Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves.
    While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.
    9

    Johnson & Johnson Savings Plan
    Notes to Financial Statements

    Valuation Hierarchy
    FASB Accounting Standards Codification (ASC) 820, Fair Value Measurements and Disclosures, provides the framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under FASB ASC 820 are described as follows:
    •Level 1 - Quoted prices in active markets for identical assets and liabilities.
    •Level 2 - Significant other observable inputs.
    •Level 3 - Significant unobservable inputs.
    A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
    The following is a description of the valuation methodologies used for the investments measured at fair value:
    •Short-term investment funds - The assets are generally comprised of quoted short-term instruments which are valued at the closing price or the amount held on deposit by the custodian bank where quoted prices are available in an active market and are classified as Level 1.  Other investments are through investment vehicles valued using the Net Asset Value ("NAV") provided by the administrator of the fund. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. The NAV is a quoted price in a market that is not active and classified as Level 2. If NAV is quoted in an active market, the investment would be classified as Level 1.
    •Government and agency securities - The assets are comprised of government and agency securities and U.S. Treasury bills and notes of varying maturities. These are all generally classified as Level 2 fair values which are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows.
    •Government and agency securities include reverse repurchase agreements. A reverse repurchase agreement, commonly known as a reverse repo, is a financial transaction where one party purchases securities from another party with a simultaneous agreement to sell them back at a later date. The price agreed upon for the repurchase is typically higher than the original sale price, reflecting an implicit interest rate known as the repo rate. Reverse repos are widely used in financial markets for liquidity management, collateralized borrowing, and short-term investment strategies. Repurchase agreements are valued based on expected settlement per the contract terms. The amounts of Reverse Repos were ($1,189,288,085) and ($1,139,063,013) in 2025 and 2024, respectively.
    •Debt instruments - The assets are comprised of corporate debt and commercial loans and mortgages. Fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are generally classified as Level 2. Level 3 debt instruments are priced based on unobservable inputs.
    •Equity securities - U.S. and International equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level 1 of the valuation hierarchy.
    •Other assets and liabilities, net - Derivatives, and related cash and securities collateral, as applicable, are included in this category. In general, derivatives that are exchange listed and actively traded are classified as Level 1, while derivatives that are not exchange listed but still actively traded in observable markets are classified as Level 2.
    •Common Collective Trusts ("CCT's") - The fair value of all CCT interests have been determined using NAV as a practical expedient. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. The CCTs are included in Investments measured at Net Asset Value. A majority of the CCTs are used for liquidity purposes for both the defined benefit and defined
    10

    Johnson & Johnson Savings Plan
    Notes to Financial Statements

    contribution plans within the Trust. The CCTs are primarily passive funds that provide daily liquidity with no prior notice for participant transactions, and 2-day prior notice for Plan Sponsor transactions for the various Plan investment options. Participant directed purchases and sales are transacted at the NAV.  At December 31, 2025 and 2024, approximately 73% and 69%, respectively, of the CCTs are invested in passive strategies that mimic the indices, and 27% and 31%, respectively, in active strategies.  Additionally, at December 31, 2025 and 2024, 63% and 61%, respectively, of the active and passive CCTs are invested in U.S. equities, 23% and 26%, respectively, are invested in global equities and emerging markets, and the remaining 14% and 13%, respectively, are invested in fixed income.  There are no unfunded commitments for any of the CCTs that the Trust invests in.
    •Limited Partnerships ("LP") - The Trust invests in LP investments including Emerging Market Long-Only Equity Funds and Private Market Funds. As of December 31, 2025 and 2024, approximately 0% and 3%, respectively, of these investments are invested in Emerging Market Long-Only Equity Funds and 100% and 97%, respectively, in Private Market Funds.
    The Trust's private market program has invested as a limited partner in a well-diversified portfolio of funds managed by general partners. The program is being managed to ensure adequate diversification by general partner, strategy type (private equity, real assets, and private credit), and geographic region. The Trust engages in co-investments alongside the general partners of the funds, as presented by them, to access attractive investments beyond the pro rata interest obtained through the fund investments. The Trust employs diverse valuation methodologies for co-investments, including multiples of earnings, discounted cash-flow analysis, and fundamental investment assessment. Factors such as financial statements, purchase price, and market observations are considered to ensure a comprehensive and accurate determination of fair value. The Trust will also assess NAV calculations from the General Partners following a similar valuation methodology. As of December 31, 2025 and 2024, approximately 58% and 58%, respectively, of these investments are invested in private equity (as of December 31, 2025 and 2024 Co-investments represent 16% and 17%, respectively, of the private equity strategy), 17% and 15%, respectively, in real assets, and 25% and 27%, respectively, in private credit. The Trust has entered into a number of private markets agreements that commit the Trust, upon request, to make additional investment purchases up to predetermined amounts. As of December 31, 2025, and 2024, the Trust had aggregate unfunded commitments of $1,842,342,412 and $2,032,793,729 respectively. These commitments are expected to be satisfied with distributions from existing funds, reinvestment of proceeds and/or periodic rebalancing of existing investments. The LP investments have target maturity dates ranging from 2026 to at least 2036 with the possibility of 2 to 4 years of extensions in accordance with the respective LP's governing documents. Distributions to the Trust from LP investments are generally driven by portfolio company liquidation in the public and private markets or other events. Otherwise, the LP investments are not redeemable. The fair value of the Trust's LP investments, excluding certain co-investments, has been determined using NAV provided by the respective general partners as a practical expedient. The NAV is the pro-rata share of the Trust's position based on the value of the underlying assets owned by the LP, minus its liabilities.

        2025 Master Trust Investments Measured at Fair Value
    Quoted market
    prices inputs
    Observable
    inputs
    Unobservable
    inputs
    Investments measured at Net Total Assets
    December 31, 2025(Level 1)(Level 2)
    (Level 3)
    Asset Value
    Short-term investment funds$— $837,401,795 $— $— $837,401,795 
    Government and agency securities— 7,909,637,860 — — 7,909,637,860 
    Debt instruments— 2,715,291,495 — — 2,715,291,495 
    Equity Securities15,822,609,084 — 611,224 — 15,823,220,308 
    Common collective trusts— — — 18,002,382,609 18,002,382,609 
    Limited Partnerships/Co-Investments— — 101,370,032 3,966,342,199 4,067,712,231 
    Other assets and liabilities, net(208,048)(11,362,733)— — (11,570,781)
    Trust investments at fair value$15,822,401,036 $11,450,968,417 $101,981,256 $21,968,724,808 $49,344,075,517 






    11

    Johnson & Johnson Savings Plan
    Notes to Financial Statements

    2024 Master Trust Investments Measured at Fair Value
    Quoted market
    prices inputs
    Observable
    inputs
    Unobservable
    inputs
    Investments measured at Net Total Assets
    December 31, 2024(Level 1)(Level 2)(Level 3) Asset Value
    Short-term investment funds$— $1,250,144,436 $— $— $1,250,144,436 
    Government and agency securities— 6,702,640,214 — — 6,702,640,214 
    Debt instruments— 2,655,972,031 — — 2,655,972,031 
    Equity securities15,780,859,727 — — — 15,780,859,727 
    Common Collective Trusts— — — 14,649,283,090 14,649,283,090 
    Limited Partnerships/Co-Investments— — 96,720,580 3,526,811,788 3,623,532,368 
    Other assets and liabilities, net(113,770,373)11,997,395 — — (101,772,978)
    Trust investments at fair value$15,667,089,354 $10,620,754,076 $96,720,580 $18,176,094,878 $44,560,658,888 
    b.    Synthetic Investment Contracts
    The Trust holds investments in synthetic GICs.  The weighted average insurance financial strength rating of the insurers for these contracts is Aa3.  These investments are recorded at their book values. The synthetic GICs’ contract value represents book value plus reinvested income adjusted for net cash flows. The synthetic GICs are fully benefit-responsive. Participants may under most circumstances direct the withdrawal or transfer of all or a portion of their investment at contract value. Currently no reserves are needed against contract values for credit risk of the contract issuers or otherwise.
    The synthetic GICs provide a return over a period of time through a fully benefit-responsive contract, or wrapper contract, which is backed by the underlying assets owned by the Trust.  The portfolio of assets with overall Aa2/AA credit quality, underlying the synthetic GICs primarily includes government and agency securities, corporate debt, mortgage backed securities, and asset backed securities. The contract value of the synthetic GICs was $1,635,918,229 and $1,768,181,421 at December 31, 2025 and December 31, 2024, respectively.
    There are certain events not initiated by Plan participants that limit the ability of the Plan to transact with the issuer of a GIC (synthetic or traditional) at its contract value. Specific coverage provided by each synthetic GIC may be different from each issuer. Examples of such events include:  the Plan’s failure to qualify under the Internal Revenue Code ("IRC") of 1986 as amended; full or partial termination of the Plan; involuntary termination of employment as a result of a corporate merger, divestiture, spin-off, or other significant business restructuring, which may include early retirement incentive programs or bankruptcy; changes to the administration of the Plan which decreases employee or employer contributions, the establishment of a competing plan by the plan sponsor, the introduction of a competing investment option, or other Plan amendment that has not been approved by the contract issuers; dissemination of a participant communication that is designed to induce participants to transfer assets from this investment option; events resulting in a material and adverse financial impact on the contract issuer, including changes in the tax code, laws or regulations.  The Plan fiduciaries believe that the occurrence of any of the aforementioned events, which would limit the Plan’s ability to transact with the issuer of a GIC at its contract value, is not probable.
    c.     Derivatives
    Presented in the following table is the fair value of derivatives within the Trust as of December 31, 2025 and 2024. The net unrealized appreciation/depreciation of these derivative instruments is included in the Interest in Johnson & Johnson Pension and Savings Plans Master Trust, at fair value in the Statements of Net Assets Available for Benefits. Derivatives are included in the Other assets and liabilities, net category in the Master Trust Table.
    12

    Johnson & Johnson Savings Plan
    Notes to Financial Statements

    20252024
    AssetLiabilityAssetLiability
    Fair Value of Derivatives
    Forward Foreign Exchange Contracts$— $581,001 $67,841 $— 
    Futures— 2,436,559 — 4,059,383 
    Interest Rate Swaps3,140,879 — 43,615 — 
    Credit Default Swaps5,947,250 — — 3,726,186 
    Options— 13,381 — 22,416 
    Total Return Swaps— 19,169,900 — 33,848,570 
    Total$9,088,129 $22,200,841 $111,456 $41,656,555 
    The following table provides information on the investment gains/(losses) on derivatives within the Trust for the year ended December 31, 2025. These amounts are included in the Plan’s interest in the Johnson & Johnson Pension and Savings Plans Master Trust net investment income/loss on the Statement of Changes in Net Assets Available for Benefits.
    2025
    Realized (Loss)/GainChange in Unrealized (Loss)/GainTotal Investment (Loss)/Gain
    Forward Foreign Exchange Contracts$519,175 $(648,842)$(129,667)
    Futures24,651,470 1,622,824 26,274,294 
    Interest Rate Swaps(246,684)3,097,264 2,850,580 
    Credit Default Swaps873,164 9,673,436 10,546,600 
    Options260,241 9,035 269,276 
    Total Return Swaps94,541,043 14,678,670 109,219,713 
    Total$120,598,409 $28,432,387 $149,030,796 

    The following table provides information on collateral pledged by and owed to the Trust as of December 31, 2025 and 2024.
    20252024
    Pledged/ (Owed)Pledged/ (Owed)
    CashCash
    Futures— — 
    Swaps4,518,000 (9,440,000)



    13

    Johnson & Johnson Savings Plan
    Notes to Financial Statements

    The following table provides the average notional value of derivatives held by the Trust as of December 31, 2025 and 2024.
    Average Notional Value
    20252024
    Purchased Forward Foreign Exchange Contracts$13,870,511 $2,327,990 
    Sold Forward Foreign Exchange Contracts33,333,526 10,323,692 
    Purchased Futures Contracts1,567,406,214 2,415,846,358 
    Sold Futures Contracts65,869,093 39,707,608 
    Purchased Options Contracts— 250,000 
    Written Options Contracts36,485,853 6,800,000 
    Interest Rate Swaps645,053,267 602,893,898 
    Written Credit Default Swaps159,491,117 182,271,163 
    Total Return Swaps1,859,844,287 1,755,247,963 

    For the written credit default swaps, the recourse provisions are determined either by the International Swaps and Derivatives Association ("ISDA") agreements or the exchange. Where the Trust is a seller of credit default swaps and if a credit event occurs due to the default of the underlying security or the underlying tranche, this would result in a net loss to the Trust. At December 31, 2025, the maximum payout for outstanding credit default swaps aggregated to $157,335,000 with terms as follows:
        
    December 31, 2025
    Number of ContractsMaturityTotal Value
    131 Year$116,530,000 
    42 Years8,275,000 
    13 Years100,000 
    24 Years1,300,000 
    35 Years6,100,000 
    26 Years9,200,000 
    17 Years2,600,000 
    28 Years1,300,000 
    29 Years3,900,000 
    110 Years8,030,000 


    At December 31, 2024, the maximum payout for outstanding credit default swaps aggregated to $162,305,000
    with terms as follows:
        
    December 31, 2024
    Number of ContractsMaturityTotal Value
    41 Year$5,600,000 
    92 Years110,930,000 
    43 Years8,275,000 
    14 Years200,000 
    35 Years10,700,000 
    27 Years9,200,000 
    28 Years8,100,000 
    29 Years1,300,000 
    110 Years8,000,000 




    14

    Johnson & Johnson Savings Plan
    Notes to Financial Statements

    4.    Notes Receivable from Participants
    The Plan had participant loans outstanding at December 31, 2025 and December 31, 2024 of $96.4 million and $93.8 million, respectively.  The net increase of $2.6 million for 2025 represents loan issuances of $51.7 million less loan retirements and payments toward outstanding loans of $49.1 million. Delinquent notes receivable from participants are reclassified to benefit payments based on terms of the Plan document.
    5.    Tax Status
    The Plan recently received a favorable determination letter from the IRS dated March 10, 2026.  Although the determination letter does not apply to certain recent amendments to the Plan, the Plan Administrator believes that the Plan is currently designed and is currently being operated in compliance with the applicable requirements of the IRC.
    Accounting principles generally accepted in the United States of America require plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the Plan has taken an uncertain tax position that more likely than not would not be sustained upon examination by the IRS.  The Plan Administrator has concluded that as of December 31, 2025 and December 31, 2024, there are no uncertain tax positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial statements.  The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress. 
    6.    Related Party Transactions
    Certain Plan investments, such as shares of CCTs managed by State Street Global Advisors, a division of State Street, and shares of State Street common stock and bonds, qualify as party-in-interest transactions as State Street was the Trustee through September 30, 2025 as defined by the Plan.  As of December 31, 2025 and December 31, 2024, the total market value of investments in these interests allocated to the Plan and managed by State Street was $11,420,918,577 and $9,755,937,102, respectively.
    Certain Plan investments managed by The Northern Trust qualify as party-in-interest transactions as The Northern Trust became the Trustee effective October 1, 2025. As of December 31, 2025, the total market value of investments in these interests allocated to the Plan and managed by The Northern Trust was $229,381,535.
    The Plan also invests in shares of the Company.  The Company is the Plan sponsor and, therefore, these transactions qualify as party-in-interest transactions. As of December 31, 2025 and December 31, 2024, the fair value of investments in Johnson & Johnson common stock was $3,443,417,665 and $2,693,242,930, respectively. During the year ended December 31, 2025, the Plan made purchases of $71,012,118 and sales of $406,545,745 of the Company’s common stock. The total dividend income received during 2025 was $90,383,792. The total realized and unrealized gains during 2025 were $205,166,824 and $883,091,812, respectively.
    7.    Asset Transfers
    As a result of business acquisitions by the Company, the following transfers into the Plan were completed in 2025:
    Plan NameAmount Transferred InDate of Transfer
    Serotiny 401(k) Plan$525,959 January 2025
    Shockwave Medical 401(k) Plan98,694,016May 2025
    Ambrx, Inc. 401(k) Plan11,131,999June 2025
    Patient Service Center LLC Savings Plan3,672,773June 2025
    V-Wave 401(k) Plan3,360,703November 2025
    15

    Johnson & Johnson Savings Plan
    Notes to Financial Statements

    8.    Reconciliation of Financial Statements to Form 5500
    The following is a reconciliation of net assets available for benefits per the financial statements to the Form 5500:
    December 31,
    20252024
    Net assets available for benefits per the financial statements
    $26,893,899,824 $23,585,553,194 
    Deemed distributions
    (731,504)(788,044)
    Amounts allocated to withdrawing participants
    (7,573,665)(4,729,325)
    Net assets available for benefits per the Form 5500
    $26,885,594,655 $23,580,035,825 
    The following is a reconciliation of the net increase in net assets available for benefits per the financial statements to the Form 5500:
    December 31, 2025
    Net increase in net assets available for benefits per the financial statements
    $3,190,961,180 
      Less: Amounts allocated to withdrawing participants at December 31, 2025 (not yet paid)
    (7,573,665)
    Less: Deemed distributions
    (95,447)
    Add: Amounts allocated to withdrawing participants at December 31, 2024
    4,729,325 
      Add: Loan offset
    151,987 
    Net increase in net assets available for benefits per the Form 5500
    $3,188,173,380 
    9. Subsequent Events

    In October 2025, the Company announced its intention to separate the Company’s Orthopedics business. The Company is targeting completion of the planned separation in 18 to 24 months after initial announcement. The Company is exploring multiple paths to effect the planned separation, with no decision at this time. The planned separation may not be completed on the terms or timeline currently contemplated, if at all, and may not achieve the expected results. The impacts of this decision is not yet known, but are being closely monitored through 2026.

    The Plan has assessed subsequent events through the date that the financial statements were available to be issued and has determined that no other items require disclosure.
    16

    Johnson & Johnson Savings Plan
    Schedule H, line 4i - Schedule of Assets (Held at End of Year)
    As of December 31, 2025



    Identity of Issue, Borrower,
    Lessor, or Similar Party
    Description of Investment
    Including Maturity Date, Rate of
    Interest, Collateral, Par or
    Maturity Value
    Cost
    Current Value
    Plan's interest in the Trust
    Plan's interest in the Johnson & Johnson Pension and Savings Plans Master Trust
    **
    $26,758,159,368 
    *Participant loans
    Interest rates ranging from 3.25% to 11.33%. Maturities ranging from 2026 - 2039
    **
    $96,395,432 


    *    Represents party-in-interest transactions
    **    Not applicable


































    17

    Johnson and Johnson Savings Plan
    Schedule H, line 4a - Schedule of Delinquent Participant Contributions
    For the year ended December 31, 2025



    Participant Contributions Transferred Late to PlanTotal that Constitute Nonexempt Prohibited TransactionTotal Fully Corrected Under VFCP and PTE 2002-51
    Check here if Late Participant Loan Repayments are included:
     q
    Contributions Not Corrected Contributions Corrected Outside VFCPContributions Pending Correction in VFCP
    $ 0
    $ 1,905*
    $ 0$ 0
    *All delinquent contributions, adjusted for earnings, have been contributed to the Plan.
    18
    Get the next $JNJ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ

    DatePrice TargetRatingAnalyst
    5/13/2026$265.00Market Perform → Outperform
    Leerink Partners
    4/8/2026$250.00Buy
    TD Cowen
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    11/13/2025$230.00Sector Outperform
    Scotiabank
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    10/3/2025$212.00Equal Weight → Overweight
    Wells Fargo
    9/23/2025$206.00Neutral → Buy
    Guggenheim
    7/23/2025Hold → Buy
    Erste Group
    More analyst ratings

    $JNJ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

    Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company's U.S. Vision operations, enhance supply chain resilience, and meet the needs of more than 40 million patients Investment is part of the Company's ongoing $55 billion commitment to U.S. manufacturing, research and development, and technology through early 2029 Building on more than 40 years of leadership in Florida, the investment supports 3,500 Jacksonville employees and strengthens Johnson & Johnson's $6 billion annual economic impact across the state Johnson & Johnson (NYSE:JNJ) (the "Company"), healthcare's leading, most comprehensive

    6/15/26 6:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

    TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the third positive study in recent months from Johnson & Johnson's bispecific portfolio and is the first Phase 3 study of a GPRC5D bispecific investigational combinationResults reinforce Johnson & Johnson's leadership in multiple myeloma, advancing bispecific combinations earlier in the treatment journey, and expanding options to match the right treatment to the right patient and stage of diseaseSTOCKHOLM, June 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announc

    6/13/26 6:33:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

    Expanded U.S. availability paired with new patient lifestyle quiz encourages informed decision-making ahead of cataract surgery. Cataracts are one of the leading causes of vision impairment.1 Nearly 20% of Americans aged 40+ live with cataracts that make everyday tasks more challenging, yet only 5% have had cataract surgery.2 Over half a million eyes worldwide have already experienced clearer, extended range of vision with TECNIS PureSee IOL after cataract surgery.3,4 97% of patients would recommend TECNIS PureSee IOL to friends or family.5 Johnson & Johnson (NYSE:JNJ) is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC-IOLs)

    6/11/26 7:45:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    SEC Filings

    View All

    SEC Form 11-K filed by Johnson & Johnson

    11-K - JOHNSON & JOHNSON (0000200406) (Filer)

    6/25/26 5:15:53 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 11-K filed by Johnson & Johnson

    11-K - JOHNSON & JOHNSON (0000200406) (Filer)

    6/25/26 5:13:18 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SD filed by Johnson & Johnson

    SD - JOHNSON & JOHNSON (0000200406) (Filer)

    5/27/26 4:15:25 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief TO and Risk Officer Wengel Kathryn E exercised 10,000 shares at a strike of $115.67 and sold $2,411,500 worth of shares (10,000 units at $241.15) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    6/12/26 5:23:31 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Woods Eugene A.

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    6/11/26 4:56:44 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Innovative Medicine, R&D Reed John C converted options into 25,255 shares and covered exercise/tax liability with 11,002 shares, increasing direct ownership by 134% to 24,911 units (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    5/4/26 4:58:59 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/12/24 5:27:36 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Johnson & Johnson from Market Perform to Outperform and set a new price target of $265.00

    5/13/26 7:59:34 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen resumed coverage on Johnson & Johnson with a new price target

    TD Cowen resumed coverage of Johnson & Johnson with a rating of Buy and set a new price target of $250.00

    4/8/26 8:36:42 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Johnson & Johnson from Equal-Weight to Overweight and set a new price target of $262.00

    1/28/26 7:11:28 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Leadership Updates

    Live Leadership Updates

    View All

    Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

    Johnson & Johnson (NYSE:JNJ) (the "Company") today announced the appointment of Ryan Koors to Vice President, Investor Relations, effective May 7, 2026. Mr. Koors will report to Johnson & Johnson's Executive Vice President and Chief Financial Officer, Joseph J. Wolk. He succeeds Darren Snellgrove who is leaving the company to become the chief financial officer of Halozyme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430443361/en/Ryan Koors, Vice President, Investor Relations, Johnson & Johnson, effective May 7, 2026. "Ryan's appointment underscores the deep bench of financial talent within Johnson & Johnson and our commitm

    4/30/26 8:02:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Financials

    Live finance-specific insights

    View All

    Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the w

    5/27/26 4:22:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

    Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a 3.1% increase in the quarterly dividend, from $1.30 per share to $1.34 per share, marking the 64th year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.36 per share compared to the previous rate of $5.20 per share. The next quarterly dividend is payable on June 9, 2026 to shareholders of record at the close of business on May 26, 2026. The ex-dividend date is May 26, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, tr

    4/14/26 6:21:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

    2026 First-Quarter reported sales growth of 9.9% to $24.1 Billion with operational growth of 6.4%* and adjusted operational growth of 5.3%* 2026 First-Quarter earnings per share (EPS) of $2.14 and adjusted EPS of $2.70 Company increases 2026 guidance with estimated reported sales of $100.8 Billion or 7.0% at the midpoint, and adjusted EPS4 of $11.55 or 7.1% at the midpoint Solidifying path to double-digit growth by the end of the decade, with significant progress for patients with the approvals of ICOTYDE the first-and-only targeted oral peptide for plaque psoriasis, TECVAYLI plus DARZALEX FASPRO as early as second line for patients with relapsed/refractory multiple myeloma, VARIP

    4/14/26 6:20:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    2/13/24 5:07:58 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    1/30/24 12:46:49 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care